|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Brazil
Espicom Business Intelligence Ltd, Sep 2009, Pages: 242
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
Due to the depreciation of Brazil’s currency against the US dollar, the Brazilian pharmaceutical market has fallen in dollar values in 2009. Controlled drug prices are increasing below inflational levels and demand is contained by a falling economic growth projected in 2009. For the industry, price controls are not directly linked to consumption levels. In fact, between 1997 and 2008, the pharmaceutical market by volume increased significantly only in 2004.
The pharmacy sector in dollar values performed exceptionally well in 2008, but the sector is starting to register slower growth in the first quarter of 2009. Generic medicines continue to grow at a higher rate than overall pharmacy sales, and are expected to represent 20% of the sector by volume in 2010. Foreign participation in the generic sector has increased following sanofi-aventis’ acquisition of Medley, recently announced in 2009.
The Chamber for the Regulation of Medicines (CMED) has authorised price increases on nearly 18,000 drug presentations which are controlled. Annual price adjustments are based on price ceilings which are calculated taking into account the National Broad Consumer Index (IPCA) between March 2008 and February 2009, a productivity factor, equal to 0.0% in 2009, and inter- and intra-sector factors.
Brazil has a history of talking tough with foreign producers. Under Decree 4,830/2003, Brazil allows compulsory licensing in cases of national emergency or public interest; Brazil issued its first compulsory licence in May 2007, for Merck Sharp & Dohme’s Stocrin (efavirenz). Rising patient numbers, increasing resistance levels, rising costs and high-risk behaviour are factors which will continue to threaten HIV/AIDS patents.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Chinese Pharmaceutical Industry
The Pharmaceutical Market: Ukraine
The Pharmaceutical Market: Argentina
Indian Pharmaceutical Industry: Issues and Opportunities
Wyeth: Performance, Products, Pipeline and Potential
The Pharmaceutical Market: Jordan
The Pharmaceutical Market: Bangladesh
Chinese Pharmaceutical Industry: Strategies, Trends and Opportunities
|
|
|
|
